Atrium Medical Corporation is proud to announce the release of the final results of the "COCTAIL Study," a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology. Dr. Francesco Prati of San Giovanni Hospital and the European Imaging Laboratory in Rome, Italy presented the results of this study at the recent TCT (Transcatheter Cardiovascular Therapeutics) meeting held in San Francisco, California. The final results demonstrated that super selective local intracoronary infusion of an anti-platelet medication known as abciximab* through the Atrium® ClearWay™ RX Local Therapeutic Infusion Catheter significantly reduced occluded coronary thrombus burden as measured by Optical Coherence Tomography (OCT) while infusion of the same dose of medication through a traditional open-ended guide catheter did not.
This first of its kind coronary occlusion study is a multi-centered, randomized, single blinded, controlled clinical trial comparing local coronary administration of the drug abciximab through a guide catheter compared with local coronary administration of abciximab using Atrium's novel infusion balloon catheter. The primary objective is to verify whether local intracoronary delivery (IC) with Atrium's ClearWay™ RX infusion balloon catheter is capable of reducing thrombus burden, confirmed by OCT imaging analysis, as compared to traditional IC guide catheter infusion (no infusion balloon). The secondary objective is to address whether the administration of abciximab by IC ClearWay™ RX, as compared to IC guide catheter delivery, can improve macro and micro circulation post intervention by measuring corrected TIMI Frame Count (cTFC) and Myocardial Blush Grade imaging scores via angiography.
SOURCE: Atrium Medical Corporation